TFO
ANIK icon

Tarbox Family Office’s Anika Therapeutics ANIK Stock Holding History

Tarbox Family Office’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-30
Closed -$1K – 1144
2021
Q1 		$1K Hold
30
– – ﹤0.01% 989
2020
Q4 		$1K Hold
30
– – ﹤0.01% 954
2020
Q3 		$1K Hold
30
– – ﹤0.01% 907
2020
Q2 		$1K Hold
30
– – ﹤0.01% 899
2020
Q1 		$1K Buy
+30
New +$1.21K ﹤0.01% 777

Other funds holding ANIK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $18.1B AUM 18.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Tarbox Family Office's ANIK Position: Q2 2021 in Review

Tarbox Family Office sold out of Anika Therapeutics (ANIK) in Q2 2021, closing a stake of 30 shares — an estimated $1K sold.

Tarbox Family Office first reported a position in ANIK in Q1 2020 and held it in 5 quarters. The position peaked at $1K in Q1 2021. 139 funds tracked by Wall St. Rank hold ANIK as of Q2 2021.

  • Tarbox Family Office reported no remaining Anika Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Tarbox Family Office sold 30 Anika Therapeutics shares in Q2 2021, an estimated $1K.
  • Tarbox Family Office first reported a position in Anika Therapeutics in Q1 2020 and held it in 5 quarters.
  • Tarbox Family Office's Anika Therapeutics position peaked at $1K in Q1 2021.
  • 139 funds tracked by Wall St. Rank held Anika Therapeutics as of Q2 2021.

Based on Tarbox Family Office's 13F filing for Q2 2021, filed 16 Jul 2021.